In this article, we will discuss 5 pharmaceutical stocks to buy today according to Tiger Cub Billionaire Lee Ainslie. If you want to read our detailed analysis of Lee Ainslie’s history, investment strategy, hedge fund performance, and some of the top pharmaceutical stocks in his 13F portfolio, go directly to the 10 Pharmaceutical Stocks to Buy Today According to Tiger Cub Billionaire Lee Ainslie.
At Insider Monkey we leave no stone unturned when looking for the next great investment idea. For example, lithium mining is one of the fastest growing industries right now, so we are checking out stock pitches like this emerging lithium stock. We go through lists like the 10 best hydrogen fuel cell stocks to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our homepage. Keeping this in mind, let’s take a look at billionaire Ainslie’s top 5 pharma stock picks:
5. Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA)
Maverick Capital’s Stake Value: $48,817,000
Percent of Maverick Capital’s 13F Portfolio: 0.45%
Number of Hedge Fund Holders: 27
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) is an American biopharmaceutical company that focuses on the discovery and development of medicines used to treat patients suffering from rare diseases.
In Q2, Maverick Capital holds over 1.3 million shares in Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), worth $48.8 million. The hedge fund sold over 44,700 shares in the company in the second quarter, reducing its position by 4%. The company currently accounts for 0.45% of the fund’s 13F portfolio. In Q2 2021, Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) posted revenue of $41.3 million, presenting a 2.2% year-over-year growth. Recently, B. Riley rated the stock as a ‘Buy’ with a $35 price target. In the past year, Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) has soared by 9.5%.
Of the 873 hedge funds tracked by Insider Monkey, 27 funds have positions in Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), worth $377.6 million.
4. Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
Maverick Capital’s Stake Value: $49,616,000
Percent of Maverick Capital’s 13F Portfolio: 0.46%
Number of Hedge Fund Holders: 33
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is a biopharmaceutical company that is focused on the discovery and development of RNAi therapeutics. The company’s RNAi-based medicines serve in four areas, such as genetic disorders, cardio-metabolic diseases, infectious diseases, and ocular diseases.
In Q2, Maverick Capital holds 292,683 shares in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), valued at $49.6 million. The company accounts for 0.46% of the fund’s 13F portfolio. In Q2 2021, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) posted an EPS of -$1.30 and revenue of $220.5 million presented a 112% year-over-year growth. Due to the strong quarter, the company lifted its FY21 guidance and now expects revenue of between $640 million to $655 million. Recently, Barclays raised its price target on Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) to $216, with an ‘Overweight’ rating on the shares. Since the beginning of the year, the stock has delivered a 56.8% return to shareholders.
As of Q2 2021, 33 hedge funds have positions in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), worth over $1.02 billion.
3. Nektar Therapeutics (NASDAQ: NKTR)
Maverick Capital’s Stake Value: $98,860,000
Percent of Maverick Capital’s 13F Portfolio: 0.92%
Number of Hedge Fund Holders: 21
Nektar Therapeutics (NASDAQ: NKTR) is a global biopharmaceutical company that develops therapies and treatments for autoimmune diseases, cancers, and chronic inflammatory disorders.
Maverick Capital holds over 5.76 million shares in Nektar Therapeutics (NASDAQ: NKTR) as of the second quarter. The shares are valued at over $98.8 million. In Q2 2021, the company posted revenue of 28.3 million, beating the consensus by $2.15 million. In June, Stifel upgraded Nektar Therapeutics (NASDAQ: NKTR) to ‘Buy’ with a $24 price target due to the company’s successful initial data on lung cancer treatment.
As of Q2 2021, 21 hedge funds have positions in Nektar Therapeutics (NASDAQ: NKTR), up from 18 in the previous quarter. The total value of these positions is $234.4 million.
2. TG Therapeutics, Inc. (NASDAQ: TGTX)
Maverick Capital’s Stake Value: $109,430,000
Percent of Maverick Capital’s 13F Portfolio: 1.02%
Number of Hedge Fund Holders: 28
TG Therapeutics, Inc. (NASDAQ: TGTX) is a biopharmaceutical company that focuses on the development of treatments for B-cell malignancies and autoimmune diseases. Currently, the company is in phase 3 for the development of treatments for multiple sclerosis and chronic lymphocytic leukemia.
In Q2 2021, Maverick Capital has over 2.8 million shares in TG Therapeutics, Inc. (NASDAQ: TGTX), worth $109.4 million. The company represents 1.02% of the hedge fund’s 13F portfolio. Recently, Cantor Fitzgerald called TG Therapeutics, Inc. (NASDAQ: TGTX) ‘a buying opportunity’ which presents significant developments in the coming months. The firm keeps an ‘Overweight’ rating on TG Therapeutics, Inc. (NASDAQ: TGTX) with a $74 price target. The company expects its net revenue for 2022 and 2025 to be $50 million to $75 million. TG Therapeutics, Inc. (NASDAQ: TGTX) gained 13.1% in the past year.
Of the 873 hedge funds tracked by Insider Monkey, 28 funds have positions in TG Therapeutics, Inc. (NASDAQ: TGTX) in Q2 2021, up from 27 in the previous quarter. These stakes are valued at $553.4 million.
1. Atara Biotherapeutics, Inc. (NASDAQ: ATRA)
Maverick Capital’s Stake Value: $119,808,000
Percent of Maverick Capital’s 13F Portfolio: 1.12%
Number of Hedge Fund Holders: 20
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) is a biotechnology company that focuses on the development of transformative therapies for patients with autoimmune disease, solid tumors, and cancers.
In Q2, Maverick Capital holds over 7.7 million shares in Atara Biotherapeutics, Inc. (NASDAQ: ATRA), worth approximately $120 million. The company accounts for 1.12% of the hedge fund’s 13F portfolio. In May, JPMorgan conducted the physician’s survey regarding the company’s phase 1 results in progressive multiple sclerosis and found the clinical significance achievable for phase 2. The firm upgraded Atara Biotherapeutics, Inc. (NASDAQ: ATRA) to ‘Overweight’ and also lifted its price target on the stock to $29. For Q2 2021, Atara Biotherapeutics, Inc. (NASDAQ: ATRA) posted revenue of $3.87 million. The stock has delivered a 4.55% return in the past year.
As of Q2 2021, 20 hedge funds tracked by Insider Monkey have positions in Atara Biotherapeutics, Inc. (NASDAQ: ATRA), the same as in the previous quarter. The total value of these stakes is $458.6 million.
You can also take a look at 10 Best Stocks To Buy According To Billionaire Larry Robbins and 10 Best Stocks To Buy Now According To Quant Billionaires.
